Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wind

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2012
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerR C Doebele, P Conkling, A M Traynor, et al.
British Journal of Pharmacology|September 24, 2010
Comparative pharmacology of chemically distinct NADPH oxidase inhibitorsS Wind, K Beuerlein, T Eucker, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 16, 2020
Evaluation and optimization of a clinical pharmacist driven transitions of care model for malignant hematologyLucas S Wind, Thomas G Knight, Jessica J Auten, et al.
Journal of the American Academy of Dermatology|January 25, 2011
Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot studyMarije W Kroon, Bas S Wind, Johan F Beek, et al.
Cancer Research|February 20, 2004
Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cureRachel L Cowen, Kaye J Williams, Edwin C Chinje, et al.
Biochemical Pharmacology|September 25, 2003
3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitroMohammed Jaffar, Roger M Phillips, Kaye J Williams, et al.
Lasers in Surgery and Medicine|September 1, 2010
Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face studyBas S Wind, Marije W Kroon, Arne A Meesters, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 3, 2010
Punchgraft testing in vitiligo; effects of UVA, NB-UVB and 632.8 nm Helium-Neon laser on the outcomeB S Wind, A A Meesters, M W Kroon, et al.
The British Journal of Dermatology|March 5, 2010
Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire studyB S Wind, M W Kroon, J F Beek, et al.
The Journal of Dermatological Treatment|July 16, 2011
Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot studyMarije W Kroon, Bas S Wind, Arne A Meesters, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2012
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerR C Doebele, P Conkling, A M Traynor, et al.
British Journal of Pharmacology|September 24, 2010
Comparative pharmacology of chemically distinct NADPH oxidase inhibitorsS Wind, K Beuerlein, T Eucker, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 16, 2020
Evaluation and optimization of a clinical pharmacist driven transitions of care model for malignant hematologyLucas S Wind, Thomas G Knight, Jessica J Auten, et al.
Journal of the American Academy of Dermatology|January 25, 2011
Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot studyMarije W Kroon, Bas S Wind, Johan F Beek, et al.
Cancer Research|February 20, 2004
Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cureRachel L Cowen, Kaye J Williams, Edwin C Chinje, et al.
Biochemical Pharmacology|September 25, 2003
3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitroMohammed Jaffar, Roger M Phillips, Kaye J Williams, et al.
Lasers in Surgery and Medicine|September 1, 2010
Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face studyBas S Wind, Marije W Kroon, Arne A Meesters, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 3, 2010
Punchgraft testing in vitiligo; effects of UVA, NB-UVB and 632.8 nm Helium-Neon laser on the outcomeB S Wind, A A Meesters, M W Kroon, et al.
The British Journal of Dermatology|March 5, 2010
Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire studyB S Wind, M W Kroon, J F Beek, et al.
The Journal of Dermatological Treatment|July 16, 2011
Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot studyMarije W Kroon, Bas S Wind, Arne A Meesters, et al.
Pageof 5